Circulating microRNAs as potential diagnostic biomarkers for osteoporosis

Osteoporosis is the most common age-related bone disease worldwide and is usually clinically asymptomatic until the first fracture happens. MicroRNAs are critical molecular regulators in bone remodelling processes and are stabilised in the blood. The aim of this project was to identify circulatory microRNAs associated with osteoporosis using advanced PCR arrays initially and the identified differentially-expressed microRNAs were validated in clinical samples using RT-qPCR. A total of 161participants were recruited and 139 participants were included in this study with local ethical approvals prior to recruitment. RNAs were extracted, purified, quantified and analysed from all serum and plasma samples. Differentially-expressed miRNAs were identified using miRNA PCR arrays initially and validated in 139 serum and 134 plasma clinical samples using RT-qPCR. Following validation of identified miRNAs in individual clinical samples using RT-qPCR, circulating miRNAs, hsa-miR-122-5p and hsa-miR-4516 were statistically significantly differentially-expressed between non-osteoporotic controls, osteopaenia and osteoporosis patients. Further analysis showed that the levels of these microRNAs were associated with fragility fracture and correlated with the low bone mineral density in osteoporosis patients. The results show that circulating hsa-miR-122-5p and hsa-miR-4516 could be potential diagnostic biomarkers for osteoporosis in the future

Loads and Movement Speeds Dictate Differences in Power Output During Circuit Training

Power training has become a common exercise intervention for improving muscle strength, power, and physical function while reducing injury risk. Few studies, however, have evaluated acute load changes on power output during traditional resistance training protocols. Therefore, the aim of this study was to quantify the effects of different loading patterns on power output during a single session of circuit resistance training (CRT). Nine male (age = 19.4 ± 0.9 years) and 11 female participants (age = 20.6 ± 1.6 years) completed 3 CRT protocols during separate testing sessions using 7 pneumatic exercises. Protocols included heavy load explosive contraction (HLEC: 80% one repetition maximum [1RM], maximum speed concentric-2 seconds eccentric), heavy load controlled contraction (HLCC: 80% 1RM, 2 seconds concentric-2 seconds eccentric), and moderate load explosive contraction (MLEC: 50% 1RM, maximum speed concentric-2 seconds eccentric). Protocols were assigned randomly using a counterbalanced design. Power for each repetition and set were determined using computerized software interfaced with each machine. Blood lactate was measured at rest and immediately postexercise. For male and female participants, average power was significantly greater during all exercises for HLEC and MLEC than HLCC. Average power was greatest during the HLEC for leg press (LP), hip adduction (ADD), and hip abduction (ABD) (p ≤ 0.05), whereas male participants alone produced their greatest power during HLEC for leg curl (LC) (p < 0.001). For male and female participants, significantly greater power was detected by set for LP, lat pull-down (LAT), ADD, LC, and ABD for the MLEC protocol (p < 0.02) and for LP, LAT, CP, and LC for the HLEC protocol (p < 0.03). A condition × sex interaction was seen for blood lactate changes ((Equation is included in full-text article.)= 0.249; p = 0.024), with female participants producing a significantly greater change for MLEC than HLEC (Mdiff = 1.61 ± 0.35 mmol·L; p = 0.011), whereas male participants showed no significant differences among conditions. Performing a CRT protocol using explosive training patterns, especially at high loads for lower-body exercises and moderate loads for upper-body exercises, produces significantly higher power than controlled speed training in most exercises. These results provide exercisers, personal trainers, and strength coaches with information that can assist in the design of training protocols to maximize power output during CRT

Aerodynamic Model Identification of Frauke UAV

This paper describes the methods and results of an identification campaign, which has been set up for the mini UAV Frauke. The estimated parameter values will be used to elaborate an accurate non-linear simulation model of the UAV, which will subsequently be used to develop model based non-linear control techniques for the vehicle. The identification procedure has been performed with the so-called two step method. First, the aircraft states are estimated based upon the aircraft kinematics, after which the aerodynamic model parameters are identified. It has been found that, due to the dynamic behaviour of the UAV, a more extended aerodynamic model including nonlinear terms is needed. Residual analysis confirms the accuracy of the obtained results

miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma.

Glioblastomas (GBMs) are the most aggressive primary brain tumors, with an average survival of less than 15 months. Therefore, there is a critical need to develop novel therapeutic strategies for GBM. This study aimed to assess the prognostic value of miR-4516 and investigate its oncogenic functions and the underlying cellular and molecular mechanisms in GBM. To determine the correlation between miR-4516 expression and overall survival of patients with GBM, total RNAs were isolated from 268 FFPE tumor samples, miR expression was assayed (simultaneously) using the nCounter human miRNA v3a assay followed by univariable and multivariable survival analyses. Further, in vitro and in vivo studies were conducted to define the role of miR-4516 in GBM tumorigenesis and the underlying molecular mechanisms. Upon multivariable analysis, miR-4516 was correlated with poor prognosis in GBM patients (HR = 1.49, 95%CI: 1.12-1.99, P = 0.01). Interestingly, the significance of miR-4516 was retained including MGMT methylation status. Overexpression of miR-4516 significantly enhanced cell proliferation and invasion of GBM cells both in vitro and in vivo. While conducting downstream targeting studies, we found that the tumor-promoting function of miR-4516, in part, was mediated by direct targeting of PTPN14 (protein tyrosine phosphatase, non-receptor type 14) which, in turn, regulated the Hippo pathway in GBM. Taken together, our data suggest that miR-4516 represents an independent negative prognostic factor in GBM patients and acts as a novel oncogene in GBM, which regulates the PTPN14/Hippo pathway. Thus, this newly identified miR-4516 may serve as a new potential therapeutic target for GBM treatment